Comparative Pharmacology
Head-to-head clinical analysis: BROMOCRIPTINE MESYLATE versus PARLODEL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BROMOCRIPTINE MESYLATE versus PARLODEL.
BROMOCRIPTINE MESYLATE vs PARLODEL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bromocriptine mesylate is a dopamine D2 receptor agonist that also exhibits partial agonist activity at D1 receptors. By stimulating dopamine receptors in the tuberoinfundibular pathway, it inhibits prolactin secretion from the anterior pituitary. It also activates postsynaptic dopamine receptors in the striatum, improving motor function in Parkinson disease. Additionally, it has been shown to improve glycemic control in type 2 diabetes by modulating central dopaminergic tone and reducing hepatic glucose production.
Dopamine D2 receptor agonist; inhibits prolactin secretion by binding to pituitary and hypothalamic D2 receptors.
Oral: 1.25-2.5 mg twice daily, increased gradually as tolerated. Maximum 100 mg/day. Also used intravaginally for hyperprolactinemia (2.5 mg once daily).
Parkinson disease: initial 1.25 mg orally twice daily, increase by 2.5 mg/day every 2-4 weeks; usual range 15-30 mg/day. Hyperprolactinemia: initial 1.25-2.5 mg orally once daily, titrate to 2.5 mg twice daily; maintenance 2.5-15 mg/day.
None Documented
None Documented
Terminal elimination half-life is approximately 6-8 hours in healthy individuals, but may be prolonged to 12-14 hours in patients with hepatic impairment or in the elderly.
Terminal elimination half-life: 12-14 hours (biphasic, initial half-life 6-8 hours); clinical context: steady-state achieved in 2-3 days.
Primarily hepatic metabolism with 85-90% fecal excretion via bile; <5% renal excretion as unchanged drug and metabolites.
Renal: approximately 60% as metabolites, 6% as unchanged drug; biliary/fecal: approximately 40% as metabolites and unchanged drug.
Category A/B
Category C
Dopamine Agonist
Dopamine Agonist